董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Helen Tayton Martin | 女 | Independent Director and Chief Executive Officer | 59 | 10.70万美元 | 27.78 | 2026-04-27 |
| Lars Holtug | 男 | Independent Director | 67 | 7.00万美元 | 48.34 | 2026-04-27 |
| Marianne Sogaard | 女 | Chairman and Independent Director | 57 | 19.60万美元 | 647.40 | 2026-04-27 |
| Roberto Prego | 男 | Independent Director | 55 | 6.40万美元 | 140.28 | 2026-04-27 |
| Lars Staal Wegner | 男 | Independent Director | 51 | 5.40万美元 | 83.79 | 2026-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Helen Tayton Martin | 女 | Independent Director and Chief Executive Officer | 59 | 10.70万美元 | 27.78 | 2026-04-27 |
| Andreas Holm Mattsson | 男 | Chief AI Officer | 50 | 36.40万美元 | 633.01 | 2026-04-27 |
| Thomas Frederik Schmidt | 男 | Chief Financial Officer | 54 | 37.60万美元 | 96.86 | 2026-04-27 |
| Birgitte Rn | 女 | Chief Scientific Officer, Chief Operating Officer | 49 | 40.20万美元 | 26.29 | 2026-04-27 |
董事简历
中英对照 | 中文 | 英文- Helen Tayton Martin
-
Helen Tayton Martin自2008年7月起担任公司首席运营官；是公司联合创始人之一。她负责公司的研发规划监管、业务开发和商业活动，包括与GSK的战略合伙企业。Tayton-Martin有着23年多的工作经验，在临床前和临床学科的发展、外包、战略规划、尽职调查和业务发展的制药、生物技术和咨询环境领域任职过。她是Adaptimmune联合创始人，之前曾在Avidex Limited subsequently Medigene任职，2005年到2008年负责癌症和HIV疗法可溶解遵行方案的商业开发。Tayton-Martin持有英国the University of Bristol分子免疫学博士学位以及Harvard Business School工商管理硕士学位。
Helen Tayton Martin, Ph.D.,Dr. Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017 having served as Chief Operating Officer since 2008 a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. Today, she is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company's strategic partnership with GlaxoSmithKline LSE/NYSE: GSK ("GSK"). She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008. Dr. Tayton-Martin also serves as a non-executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School. - Helen Tayton Martin自2008年7月起担任公司首席运营官；是公司联合创始人之一。她负责公司的研发规划监管、业务开发和商业活动，包括与GSK的战略合伙企业。Tayton-Martin有着23年多的工作经验，在临床前和临床学科的发展、外包、战略规划、尽职调查和业务发展的制药、生物技术和咨询环境领域任职过。她是Adaptimmune联合创始人，之前曾在Avidex Limited subsequently Medigene任职，2005年到2008年负责癌症和HIV疗法可溶解遵行方案的商业开发。Tayton-Martin持有英国the University of Bristol分子免疫学博士学位以及Harvard Business School工商管理硕士学位。
- Helen Tayton Martin, Ph.D.,Dr. Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017 having served as Chief Operating Officer since 2008 a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. Today, she is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company's strategic partnership with GlaxoSmithKline LSE/NYSE: GSK ("GSK"). She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008. Dr. Tayton-Martin also serves as a non-executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.
- Lars Holtug
-
Lars Holtug自2018年11月以来一直担任我们的董事会成员。Holtug从1993年到2015年担任普华永道会计师事务所（PricewaterhouseCoopers Statsautoriseret修正版Partnerselskab“；PwC”；）合伙人。Holtug先生目前还担任Gaming Investment A/S公司（一家游戏解决方案提供商）及其10家子公司以及MTI Caretag APS公司（一家投资于梦百合技术的公司）的董事长。此前，他曾担任丹麦PwC公司的主席（从2005年到2009年）。从2004年到2015年，Holtug先生是丹麦商业上诉委员会（ErhvervSankenaevnet）的成员，也是丹麦公司法协会（Dansk Forening for Selskabsret）的董事会成员。他也曾担任the Federation of State Authorisered Accountants in Denmark（Foreningen AF Statsautoriserede审校）的会计准则委员会的成员（1998年至2002年），以及审计准则委员会的成员（1993年至1998年）。Holtug先生拥有硕士学位。毕业于哥本哈根商学院（Copenhagen Business School），并在丹麦接受国家授权会计师的教育。
Lars Holtug has served as a member of board of directors since November 2018. Mr. Holtug was a partner at PricewaterhoeCoopers Statsautoriseret Revisionspartnerselskab ("PwC") from 1993 to 2015. Mr. Holtug also currently serves as chairman of Erhvervsinvest Management A/S, a private equity firm, Gaming Investment A/S, a gaming solutions provider, and its seven subsidiaries, and of Caretag A/S, a healthcare technology company. Mr. Holtug also currently serves as a board member of Evaxion Biotech A/S, as ll as the Audit Committee Chair and Remuneration Committee member. Previoly, he was Chairman of PwC in Denmark from 2005 to 2009. From 2004 to 2015, Mr. Holtug was a member of the Danish Commercial Appeals Board (Erhvervsankenaevnet) and a board member of the Danish Company law association (Dansk Forening for Selskabsret). He was also a member of the Accounting Standards Board of the Federation of State Authorized Accountants in Denmark (Foreningen af Statsautoriseret Revisorer) from 1998 to 2002, and a member of the Auditing Standards Board from 1993 to 1998. Mr. Holtug holds an M.Sc. from Copenhagen Biness School and is educated as a state authorized public accountant in Denmark. - Lars Holtug自2018年11月以来一直担任我们的董事会成员。Holtug从1993年到2015年担任普华永道会计师事务所（PricewaterhouseCoopers Statsautoriseret修正版Partnerselskab“；PwC”；）合伙人。Holtug先生目前还担任Gaming Investment A/S公司（一家游戏解决方案提供商）及其10家子公司以及MTI Caretag APS公司（一家投资于梦百合技术的公司）的董事长。此前，他曾担任丹麦PwC公司的主席（从2005年到2009年）。从2004年到2015年，Holtug先生是丹麦商业上诉委员会（ErhvervSankenaevnet）的成员，也是丹麦公司法协会（Dansk Forening for Selskabsret）的董事会成员。他也曾担任the Federation of State Authorisered Accountants in Denmark（Foreningen AF Statsautoriserede审校）的会计准则委员会的成员（1998年至2002年），以及审计准则委员会的成员（1993年至1998年）。Holtug先生拥有硕士学位。毕业于哥本哈根商学院（Copenhagen Business School），并在丹麦接受国家授权会计师的教育。
- Lars Holtug has served as a member of board of directors since November 2018. Mr. Holtug was a partner at PricewaterhoeCoopers Statsautoriseret Revisionspartnerselskab ("PwC") from 1993 to 2015. Mr. Holtug also currently serves as chairman of Erhvervsinvest Management A/S, a private equity firm, Gaming Investment A/S, a gaming solutions provider, and its seven subsidiaries, and of Caretag A/S, a healthcare technology company. Mr. Holtug also currently serves as a board member of Evaxion Biotech A/S, as ll as the Audit Committee Chair and Remuneration Committee member. Previoly, he was Chairman of PwC in Denmark from 2005 to 2009. From 2004 to 2015, Mr. Holtug was a member of the Danish Commercial Appeals Board (Erhvervsankenaevnet) and a board member of the Danish Company law association (Dansk Forening for Selskabsret). He was also a member of the Accounting Standards Board of the Federation of State Authorized Accountants in Denmark (Foreningen af Statsautoriseret Revisorer) from 1998 to 2002, and a member of the Auditing Standards Board from 1993 to 1998. Mr. Holtug holds an M.Sc. from Copenhagen Biness School and is educated as a state authorized public accountant in Denmark.
- Marianne Sogaard
-
Marianne Sogaard于2018年加入我们，担任执行和法律顾问，并于2020年11月当选并成为我们的董事会主席。S&248；Gaard女士于2006年加入Kammeradvokaten/律师事务所Poul Schmith，在那里她担任了20多年的律师，主要从事技术和流程的工作，以获取技术解决方案。在超过17年的时间里，S&248；Gaard女士是Kammeradvokaten/律师事务所Paul Schmith的合伙人，并于2014年1月至2017年3月担任该律师事务所的董事会成员。Sø；Gaard女士在各种私人控股公司担任董事会成员，包括在小型创业食品公司Garbanzo APS担任董事会主席，How to Robot APS，这是一个支持为客户和供应商收购实体机器人的平台，Homemate APS，一家即食烹饪食品公司，以及Altapay A/S，一家支付解决方案公司。S&248；Gaard女士于1993年在奥豪斯大学（Aarhaus Universitet）获得法学硕士学位。
Marianne Sogaard,joined in 2018 as an executive and legal advisor and in November 2020 she was elected and became the Chairman of board of directors. In 1996, Ms. Sgaard joined Kammeradvokaten/Law Firm Poul Schmith where she worked for more than 20 years as a lawyer, primarily working with technology and processes to acquire technology solutions. For more than 17 years, Ms. Sgaard was a partner at Kammeradvokaten/Law Firm Poul Schmith and from January 2014 to March 2017 she served on the board of directors of the law firm. Ms. Sgaard serves as a member of the board of directors at various privately held companies, including as the chairperson of the board at Garbanzo ApS, a small startup food company, Homemate ApS, a ready to cook food company, and Altapay A/S, a payment solution company. Ms. Sgaard received her Master of Law degree from Aarhus Universitet in 1993. - Marianne Sogaard于2018年加入我们，担任执行和法律顾问，并于2020年11月当选并成为我们的董事会主席。S&248；Gaard女士于2006年加入Kammeradvokaten/律师事务所Poul Schmith，在那里她担任了20多年的律师，主要从事技术和流程的工作，以获取技术解决方案。在超过17年的时间里，S&248；Gaard女士是Kammeradvokaten/律师事务所Paul Schmith的合伙人，并于2014年1月至2017年3月担任该律师事务所的董事会成员。Sø；Gaard女士在各种私人控股公司担任董事会成员，包括在小型创业食品公司Garbanzo APS担任董事会主席，How to Robot APS，这是一个支持为客户和供应商收购实体机器人的平台，Homemate APS，一家即食烹饪食品公司，以及Altapay A/S，一家支付解决方案公司。S&248；Gaard女士于1993年在奥豪斯大学（Aarhaus Universitet）获得法学硕士学位。
- Marianne Sogaard,joined in 2018 as an executive and legal advisor and in November 2020 she was elected and became the Chairman of board of directors. In 1996, Ms. Sgaard joined Kammeradvokaten/Law Firm Poul Schmith where she worked for more than 20 years as a lawyer, primarily working with technology and processes to acquire technology solutions. For more than 17 years, Ms. Sgaard was a partner at Kammeradvokaten/Law Firm Poul Schmith and from January 2014 to March 2017 she served on the board of directors of the law firm. Ms. Sgaard serves as a member of the board of directors at various privately held companies, including as the chairperson of the board at Garbanzo ApS, a small startup food company, Homemate ApS, a ready to cook food company, and Altapay A/S, a payment solution company. Ms. Sgaard received her Master of Law degree from Aarhus Universitet in 1993.
- Roberto Prego
-
Roberto Prego于2018年加入我们。Prego先生拥有超过20年的制药经验，是我们最早的外部投资者之一。Prego先生于1998年至2012年在Teva Venezuela担任总经理，并于2011年至2015年在Teva Latin American Region担任区域主管。自2015年以来，他一直担任Viax Dental Technologies（牙科领域研究与开发的风险投资公司）的总经理。Prego先生在委内瑞拉加拉加斯的Universidad Cat&243；Lica Andr&233；s Bello获得经济学学士学位，并在杜克大学Fuqua商学院获得工商管理硕士学位。
Roberto Prego,has over 20 years of pharmaceutical experience and was one of first outside investors. Mr. Prego was with Teva Venezuela as its General Manager from 1998 to 2012 and with Teva Latin American Region as its Head of Region from 2011 to 2015. Since 2015, he has served as the General Manager of Viax Dental Technologies, a research and development venture firm in the dental field. Mr. Prego has a B.S. in Economics from Universidad Católica Andrés Bello in Caracas, Venezuela and an M.B.A. from Fuqua School of Business at Duke University. - Roberto Prego于2018年加入我们。Prego先生拥有超过20年的制药经验，是我们最早的外部投资者之一。Prego先生于1998年至2012年在Teva Venezuela担任总经理，并于2011年至2015年在Teva Latin American Region担任区域主管。自2015年以来，他一直担任Viax Dental Technologies（牙科领域研究与开发的风险投资公司）的总经理。Prego先生在委内瑞拉加拉加斯的Universidad Cat&243；Lica Andr&233；s Bello获得经济学学士学位，并在杜克大学Fuqua商学院获得工商管理硕士学位。
- Roberto Prego,has over 20 years of pharmaceutical experience and was one of first outside investors. Mr. Prego was with Teva Venezuela as its General Manager from 1998 to 2012 and with Teva Latin American Region as its Head of Region from 2011 to 2015. Since 2015, he has served as the General Manager of Viax Dental Technologies, a research and development venture firm in the dental field. Mr. Prego has a B.S. in Economics from Universidad Católica Andrés Bello in Caracas, Venezuela and an M.B.A. from Fuqua School of Business at Duke University.
- Lars Staal Wegner
-
Lars Staal Wegner于2017年8月加入我们，担任我们的首席执行官。Wegner博士是我们的创始投资者之一，此前曾参与多个初创公司和早期风险投资。Wegner博士作为一名医生开始了他的职业生涯，并担任了几年的临床医生。从那时起，韦格纳博士在疫苗行业获得了丰富的经验，最初于2006年至2007年在辉瑞工作，然后于2007年至2017年在纳斯达克上市的免疫肿瘤学和疫苗公司Bavarian Nordic担任了十年的高级管理人员。Wegner博士在南丹麦大学（University of Southern Denmark）获得医学博士学位。
Lars Staal Wegner,was Chairman of the Board from 2013-2014, member of the board from 2015 to 2016 and was elected as CEO in July 2017, which he stepped down from in September 2022 and was then elected as a member of the board of directors in April 2024. Mr. Wegner works as VP of Business Development at Hengrui Pharmaceuticals, leading global pharmaceutical company committed to promoting a healthier life for humankind through advancements in science. He has helped build numerous biotech, diagnostics, and IT companies, sitting on multiple boards. Earlier in his career, he held different roles of increasing responsibility at Bavarian Nordic A/S, including as Vice President of Commercial Affairs, during which time he contributed to developing the company's Ebola vaccine and different previous roles in Pfizer. - Lars Staal Wegner于2017年8月加入我们，担任我们的首席执行官。Wegner博士是我们的创始投资者之一，此前曾参与多个初创公司和早期风险投资。Wegner博士作为一名医生开始了他的职业生涯，并担任了几年的临床医生。从那时起，韦格纳博士在疫苗行业获得了丰富的经验，最初于2006年至2007年在辉瑞工作，然后于2007年至2017年在纳斯达克上市的免疫肿瘤学和疫苗公司Bavarian Nordic担任了十年的高级管理人员。Wegner博士在南丹麦大学（University of Southern Denmark）获得医学博士学位。
- Lars Staal Wegner,was Chairman of the Board from 2013-2014, member of the board from 2015 to 2016 and was elected as CEO in July 2017, which he stepped down from in September 2022 and was then elected as a member of the board of directors in April 2024. Mr. Wegner works as VP of Business Development at Hengrui Pharmaceuticals, leading global pharmaceutical company committed to promoting a healthier life for humankind through advancements in science. He has helped build numerous biotech, diagnostics, and IT companies, sitting on multiple boards. Earlier in his career, he held different roles of increasing responsibility at Bavarian Nordic A/S, including as Vice President of Commercial Affairs, during which time he contributed to developing the company's Ebola vaccine and different previous roles in Pfizer.
高管简历
中英对照 | 中文 | 英文- Helen Tayton Martin
Helen Tayton Martin自2008年7月起担任公司首席运营官；是公司联合创始人之一。她负责公司的研发规划监管、业务开发和商业活动，包括与GSK的战略合伙企业。Tayton-Martin有着23年多的工作经验，在临床前和临床学科的发展、外包、战略规划、尽职调查和业务发展的制药、生物技术和咨询环境领域任职过。她是Adaptimmune联合创始人，之前曾在Avidex Limited subsequently Medigene任职，2005年到2008年负责癌症和HIV疗法可溶解遵行方案的商业开发。Tayton-Martin持有英国the University of Bristol分子免疫学博士学位以及Harvard Business School工商管理硕士学位。
Helen Tayton Martin, Ph.D.,Dr. Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017 having served as Chief Operating Officer since 2008 a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. Today, she is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leaing on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company's strategic partnership with GlaxoSmithKline LSE/NYSE: GSK ("GSK"). She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008. Dr. Tayton-Martin also serves as a non-executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.- Helen Tayton Martin自2008年7月起担任公司首席运营官；是公司联合创始人之一。她负责公司的研发规划监管、业务开发和商业活动，包括与GSK的战略合伙企业。Tayton-Martin有着23年多的工作经验，在临床前和临床学科的发展、外包、战略规划、尽职调查和业务发展的制药、生物技术和咨询环境领域任职过。她是Adaptimmune联合创始人，之前曾在Avidex Limited subsequently Medigene任职，2005年到2008年负责癌症和HIV疗法可溶解遵行方案的商业开发。Tayton-Martin持有英国the University of Bristol分子免疫学博士学位以及Harvard Business School工商管理硕士学位。
- Helen Tayton Martin, Ph.D.,Dr. Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017 having served as Chief Operating Officer since 2008 a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. Today, she is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leaing on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company's strategic partnership with GlaxoSmithKline LSE/NYSE: GSK ("GSK"). She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008. Dr. Tayton-Martin also serves as a non-executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.
- Andreas Holm Mattsson
Andreas Holm Mattsson是我们的创始人之一，自我们成立以来一直担任我们的首席创新官。Mattsson先生是丹麦技术大学（Technical University of Denmark）的一位经验丰富的生物信息学家。加入公司之前，Mattsson从2004年到2011年在Novo Nordisk任职，在Silico Platforms开发。自2008年创立EVAXION以来，Andreas一直致力于开发EVAXION的AI平台，包括Eden和Pioneer，以及其他有助于免疫肿瘤学和传染病领域疫苗发现和开发的Silico模型。
Andreas Holm Mattsson,is founder of Evaxion and has served as Chief AI Officer. Mr. Mattsson has been at the forefront in silico-based vaccine target discovery. He has played a key role in developing Evaxion's innovative AI-Immunology platform, a proprietary AI technology for identifying novel vaccine targets for cancer and infectious diseases. Since founding Evaxion in 2008, he has been an essential part of the company's growth, serving in various executive roles.- Andreas Holm Mattsson是我们的创始人之一，自我们成立以来一直担任我们的首席创新官。Mattsson先生是丹麦技术大学（Technical University of Denmark）的一位经验丰富的生物信息学家。加入公司之前，Mattsson从2004年到2011年在Novo Nordisk任职，在Silico Platforms开发。自2008年创立EVAXION以来，Andreas一直致力于开发EVAXION的AI平台，包括Eden和Pioneer，以及其他有助于免疫肿瘤学和传染病领域疫苗发现和开发的Silico模型。
- Andreas Holm Mattsson,is founder of Evaxion and has served as Chief AI Officer. Mr. Mattsson has been at the forefront in silico-based vaccine target discovery. He has played a key role in developing Evaxion's innovative AI-Immunology platform, a proprietary AI technology for identifying novel vaccine targets for cancer and infectious diseases. Since founding Evaxion in 2008, he has been an essential part of the company's growth, serving in various executive roles.
- Thomas Frederik Schmidt
Thomas Frederik Schmidt，自2024年11月1日起担任首席财务官。施密特先生带来了30多年来自不同行业的财务管理经验，其中超过26年立足于生命科学行业，包括在罗氏担任国家董事总经理和国家首席财务官，在Ambu（一家在纳斯达克哥本哈根证券交易所上市的医疗技术公司）担任集团首席财务官。Schmidt先生拥有哥本哈根商学院商业经济和审计理学硕士学位，并接受过国家授权公共会计师（CPA）考试的培训和准备。
Thomas Frederik Schmidt was permanently appointed in November 2025, having joined Evaxion on an interim basis on November 1, 2024. Mr. Schmidt has more than 30 years of financial management experience from across different indtries with more than 25 years of these being based in the life science industry including roles as country Managing Director and country Chief Financial Officer in Roche and Group CFO in Ambu.- Thomas Frederik Schmidt，自2024年11月1日起担任首席财务官。施密特先生带来了30多年来自不同行业的财务管理经验，其中超过26年立足于生命科学行业，包括在罗氏担任国家董事总经理和国家首席财务官，在Ambu（一家在纳斯达克哥本哈根证券交易所上市的医疗技术公司）担任集团首席财务官。Schmidt先生拥有哥本哈根商学院商业经济和审计理学硕士学位，并接受过国家授权公共会计师（CPA）考试的培训和准备。
- Thomas Frederik Schmidt was permanently appointed in November 2025, having joined Evaxion on an interim basis on November 1, 2024. Mr. Schmidt has more than 30 years of financial management experience from across different indtries with more than 25 years of these being based in the life science industry including roles as country Managing Director and country Chief Financial Officer in Roche and Group CFO in Ambu.
- Birgitte Rn
Birgitte R n ，自2021年起担任首席科学官，于2017年加入Evaxion。R n 博士在学术界和工业界拥有超过25年的生物制药药物发现经验，并在美国贝塞斯达国立卫生研究院和丹麦哥本哈根大学医院获得实验肿瘤学和免疫学博士学位。在加入Evaxion之前，Birgitte R n 曾在Novo Nordisk A/S担任专家、团队负责人和项目经理，负责领导早期药物发现项目、评估许可机会，并支持具有临床前和生物标志物专业知识的药物开发项目。
Birgitte Rn joined in 2017 and was appointed CSO in 2021. Dr. Rn has more than 25 years' experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, A, and Copenhagen University Hospital, Denmark. Prior to joining Evaxion, Birgitte Rn served as a specialist, team leader and project manager at Novo Nordisk A/S, where she was leading early drug discovery projects, evaluating in licensing opportunities, and supporting drug development projects with preclinical and biomarker expertise.- Birgitte R n ，自2021年起担任首席科学官，于2017年加入Evaxion。R n 博士在学术界和工业界拥有超过25年的生物制药药物发现经验，并在美国贝塞斯达国立卫生研究院和丹麦哥本哈根大学医院获得实验肿瘤学和免疫学博士学位。在加入Evaxion之前，Birgitte R n 曾在Novo Nordisk A/S担任专家、团队负责人和项目经理，负责领导早期药物发现项目、评估许可机会，并支持具有临床前和生物标志物专业知识的药物开发项目。
- Birgitte Rn joined in 2017 and was appointed CSO in 2021. Dr. Rn has more than 25 years' experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, A, and Copenhagen University Hospital, Denmark. Prior to joining Evaxion, Birgitte Rn served as a specialist, team leader and project manager at Novo Nordisk A/S, where she was leading early drug discovery projects, evaluating in licensing opportunities, and supporting drug development projects with preclinical and biomarker expertise.